BAP1 and neoplasm: Due to BAP1 immunomodulatory functions, as well as lymphocyte infiltration and inflammatory tumor environment seen in some BAP1-deficient tumors, BAP1 alterations are seen as possible biomarkers that may help predict response to immunotherapy [11].